# Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)

> **NCT00083980** · PHASE2 · TERMINATED · sponsor: **National Center for Complementary and Integrative Health (NCCIH)** · enrollment: 16 (actual)

## Conditions studied

- Anxiety Disorders

## Interventions

- **DRUG:** Venlafaxine ER
- **DRUG:** Sugar pill
- **DRUG:** Kava

## Key facts

- **NCT ID:** NCT00083980
- **Lead sponsor:** National Center for Complementary and Integrative Health (NCCIH)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06
- **Primary completion:** 2004-06
- **Final completion:** 2004-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** European reports of liver toxicity from kava meant that the study had to stop
- **Last updated:** 2012-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083980, "Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00083980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*